Newsroom | 5009 results

BALTIMORE--(BUSINESS WIRE)--Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, celebrates the inspiring health transformation of Tiffany Howard, recently featured in People magazine. Tiffany’s journey highlights how OPTAVIA’s comprehensive program, which combines science-backed nutrition, personalized coaching and sustainable habit-building, reversed her metabolic dysfunction1. For Tiffany, this meant several meaningful he...

ZURIGO, PHILADELPHIA e COPENHAGEN, Danimarca--(BUSINESS WIRE)--InterAx Biotech Ltd (“InterAx”) e Alveus Therapeutics Inc. (“Alveus”) oggi hanno annunciato un accordo strategico di licenza e collaborazione alla ricerca volto a sviluppare un candidato differenziato a piccola molecola per la malattia metabolica per offrire una terapia dimagrante durevole con tollerabilità superiore. Questa collaborazione fa parte di uno impegno di ricerca congiunta su un target e una modalità di interesse terapeut...

ZÜRICH & PHILADELPHIA & KOPENHAGEN, Denemarken--(BUSINESS WIRE)--InterAx Biotech Ltd ('InterAx') en Alveus Therapeutics Inc. ('Alveus') hebben vandaag een strategische samenwerkings- en licentieovereenkomst aangekondigd voor de ontwikkeling van een onderscheidend kandidaatmedicijn met kleine moleculen voor stofwisselingsziekten, gericht op duurzaam gewichtsverlies met een superieure verdraagbaarheid. Dit partnerschap vormt een gezamenlijke onderzoeksinspanning gericht op een doelwit en modalite...

ZÜRICH, PHILADELPHIA UND KOPENHAGEN, Dänemark--(BUSINESS WIRE)--InterAx Biotech Ltd („InterAx“) und Alveus Therapeutics Inc. („Alveus“) haben heute eine strategische Forschungskooperation und Lizenzvereinbarung zur Entwicklung eines differenzierten niedermolekularen Arzneimittelkandidaten für Stoffwechselerkrankungen bekannt gegeben, der eine dauerhafte Gewichtsreduktion bei hervorragender Verträglichkeit verspricht. Im Rahmen dieser Partnerschaft wird eine gemeinsame Forschungsinitiative zu ei...

ZURICH, PHILADELPHIE et COPENHAGUE, Danemark--(BUSINESS WIRE)--InterAx Biotech Ltd (« InterAx ») et Alveus Therapeutics Inc. (« Alveus ») ont annoncé aujourd'hui un accord de collaboration stratégique en matière de recherche et contrat de licence visant à développer une petite molécule candidate différenciée pour les maladies métaboliques afin d'obtenir une perte de poids durable ayant une meilleure une tolérance. Ce partenariat s'inscrit dans une recherche conjointe sur une cible et une modali...

ZURICH y FILADELFIA Y COPENHAGUE, Dinamarca--(BUSINESS WIRE)--InterAx Biotech Ltd (“InterAx”) y Alveus Therapeutics Inc. (“Alveus”) anunciaron hoy una colaboración estratégica de investigación y un acuerdo de licencia para desarrollar un candidato diferenciado de molécula pequeña destinado al tratamiento de enfermedades metabólicas, con el objetivo de lograr una pérdida de peso duradera y una tolerabilidad superior. Esta alianza establece un esfuerzo conjunto de investigación sobre un objetivo...

BALTIMORE--(BUSINESS WIRE)--Medifast® (NYSE: MED), the health and wellness company known for its science-backed, coach-guided lifestyle system OPTAVIA, premiered its newest docuseries episode, “Health by Design: Spain”, which explores the cultural, environmental, and community-driven factors promoting long, healthy lives. The second installment in the “Health by Design” series transports viewers to Galicia and Madrid, Spain – spotlighting Galicia, a region renowned for its potential to become t...

ZURICH & PHILADELPHIA & COPENHAGEN, Denmark--(BUSINESS WIRE)--InterAx Biotech Ltd (“InterAx”) and Alveus Therapeutics Inc. (“Alveus”) today announced a strategic research collaboration and licensing agreement to develop a differentiated small molecule candidate for metabolic disease to deliver durable weight loss with superior tolerability. This partnership forms a joint research effort on a target and modality of established but untapped therapeutic interest by combining InterAx’s Deep Signal™...

DUBLIN--(BUSINESS WIRE)--The "Peptide Therapeutics Market: Industry Trends and Global Forecasts, Till 2040 - Distribution by Type of Peptide, Route of Administration, Key Therapeutic Area and Geographical Regions" has been added to ResearchAndMarkets.com's offering. The peptide therapeutics market is poised for significant growth, projected to escalate from USD 84.2 billion in 2023 to USD 162.4 billion by 2035, marking a CAGR of 6.8%. These therapeutics, built from polypeptides, are increasingl...

ROCHDALE, United Kingdom--(BUSINESS WIRE)--Astoriom today announced the appointment of Will Edwards, MBA as CEO to support global scale-up of sample management operations....